These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20487001)

  • 1. Cholinergic autoantibodies from primary Sjögren's syndrome modulate submandibular gland Na+/K+-ATPase activity via prostaglandin E2 and cyclic AMP.
    Passafaro D; Reina S; Sterin-Borda L; Borda E
    Eur J Oral Sci; 2010 Apr; 118(2):131-8. PubMed ID: 20487001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Action of anti-M₃muscarinic acetylcholine receptor IgG of primary Sjögren's syndrome on the enzymatic antioxidant system in rat submandibular gland.
    Reina S; Rodríguez M; Stranieri G; Borda E
    J Oral Pathol Med; 2015 Nov; 44(10):876-83. PubMed ID: 25726719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome.
    Waterman SA; Gordon TP; Rischmueller M
    Arthritis Rheum; 2000 Jul; 43(7):1647-54. PubMed ID: 10902771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches.
    Dawson LJ; Allison HE; Stanbury J; Fitzgerald D; Smith PM
    Rheumatology (Oxford); 2004 Dec; 43(12):1488-95. PubMed ID: 15353609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-brain cholinergic auto antibodies from primary Sjögren syndrome sera modify simultaneously cerebral nitric oxide and prostaglandin biosynthesis.
    Orman B; Sterin-Borda L; De Couto Pita A; Reina S; Borda E
    Int Immunopharmacol; 2007 Dec; 7(12):1535-43. PubMed ID: 17920530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells.
    Dawson LJ; Stanbury J; Venn N; Hasdimir B; Rogers SN; Smith PM
    Arthritis Rheum; 2006 Apr; 54(4):1165-73. PubMed ID: 16572451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren's syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands.
    Reina S; Sterin-Borda L; Passafaro D; Borda E
    Arch Oral Biol; 2011 May; 56(5):413-20. PubMed ID: 21371688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren's syndrome.
    Bacman S; Perez Leiros C; Sterin-Borda L; Hubscher O; Arana R; Borda E
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):151-6. PubMed ID: 9430556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Antimuscarinic Autoantibodies in Primary Sjögren's Syndrome.
    Kim N; Shin Y; Choi S; Namkoong E; Kim M; Lee J; Song Y; Park K
    J Dent Res; 2015 May; 94(5):722-8. PubMed ID: 25784251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors.
    Bacman SR; Berra A; Sterin-Borda L; Borda ES
    Curr Eye Res; 1998 Dec; 17(12):1135-42. PubMed ID: 9872535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive transfer of Sjogren's syndrome IgG produces the pathophysiology of overactive bladder.
    Wang F; Jackson MW; Maughan V; Cavill D; Smith AJ; Waterman SA; Gordon TP
    Arthritis Rheum; 2004 Nov; 50(11):3637-45. PubMed ID: 15529387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjogren's syndrome patients.
    Koo NY; Li J; Hwang SM; Choi SY; Lee SJ; Oh SB; Kim JS; Lee EB; Song YW; Park K
    Rheumatology (Oxford); 2008 Jun; 47(6):828-33. PubMed ID: 18400835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome.
    Bacman S; Sterin-Borda L; Camusso JJ; Arana R; Hubscher O; Borda E
    Clin Exp Immunol; 1996 Jun; 104(3):454-9. PubMed ID: 9099930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome.
    Bacman S; Berra A; Sterin-Borda L; Borda E
    Invest Ophthalmol Vis Sci; 2001 Feb; 42(2):321-7. PubMed ID: 11157861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin inhibits the inflammatory response caused by anti-M(3) peptide IgG in patients with primary Sjögren's syndrome.
    Reina S; Passafaro D; Sterin-Borda L; Borda E
    Inflammopharmacology; 2012 Oct; 20(5):267-75. PubMed ID: 22441579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-M(3) peptide IgG from Sjögren's syndrome triggers apoptosis in A253 cells.
    Reina S; Sterin-Borda L; Borda E
    Cell Immunol; 2012; 275(1-2):33-41. PubMed ID: 22513175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies in primary Sjögren's syndrome patients induce internalization of muscarinic type 3 receptors.
    Jin M; Hwang SM; Davies AJ; Shin Y; Bae JS; Lee JH; Lee EB; Song YW; Park K
    Biochim Biophys Acta; 2012 Feb; 1822(2):161-7. PubMed ID: 22137887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies in Sjögren's syndrome patients acutely inhibit muscarinic receptor function.
    Jin M; Hwang SM; Koo NY; Kim B; Kho HS; Choi SY; Song YW; Park K
    Oral Dis; 2012 Mar; 18(2):132-9. PubMed ID: 21899666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinoreceptor autoantibodies in Sjögren syndrome.
    Reina S; Orman B; Anaya JM; Sterin-Borda L; Borda E
    J Dent Res; 2007 Sep; 86(9):832-6. PubMed ID: 17720850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies against cerebral muscarinic cholinoceptors in Sjögren syndrome: functional and pathological implications.
    Reina S; Sterin-Borda L; Orman B; Borda E
    J Neuroimmunol; 2004 May; 150(1-2):107-15. PubMed ID: 15081254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.